# Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

> **NCT05130866** · PHASE2,PHASE3 · TERMINATED · sponsor: **Recursion Pharmaceuticals Inc.** · enrollment: 25 (actual)

## Conditions studied

- Neurofibromatosis Type 2

## Interventions

- **DRUG:** REC-2282
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05130866
- **Lead sponsor:** Recursion Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-20
- **Primary completion:** 2025-08-18
- **Final completion:** 2025-08-18
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Study was terminated due to sponsor decision. This decision was not related to safety concerns with REC-2282.
- **Last updated:** 2025-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05130866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05130866, "Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05130866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*